Immunization before immunosuppression: pediatric checklist

Not by parental refusal — the chart shows an age-appropriate primary series completed — but because the live-attenuated boosters, annual influenza updates, and catch-up doses have fallen through scheduling cracks during chronic disease follow-up. Once we initiate biologic therapy or high-dose corticosteroids, the window for safe live-vaccine administration slams shut, often for months. The resulting cohort is exposed to preventable infections during their most immunologically vulnerable stretch.

In my experience running these cohorts, the single most consequential pre-screening decision happens before any biologic infusion order is written. The 2021 EULAR/PENTA update on pediatric rheumatic disease vaccination and the 2025 IDSA guideline on vaccines in immunocompromised patients both make this explicit: review the immunization record, then time the immunosuppression. The reality on the ground is messier — rheumatologists, nephrologists, and oncologists often need to start therapy within days, not weeks. This checklist is built for that tension.

The immunization window is not a window of convenience. It is the only phase in which live-attenuated vaccines can be safely administered to a child who is about to become profoundly immunosuppressed.

Strategic timing for live and inactivated vaccines

The textbook numbers are not negotiable, but they are routinely compressed under clinical pressure. For children scheduled to begin immunosuppressive therapy, the standard pediatric pre immunosuppression vaccine checklist dictates two distinct lead times:

• Live virus vaccines — MMR, MMRV, varicella — should be administered at least 4 weeks before the planned start of immunosuppressive therapy.
• Inactivated vaccines — DTaP, Hib, hepatitis B, pneumococcal conjugate (PCV13/PCV15/PCV20), inactivated polio (IPV), hepatitis A, and the annual inactivated influenza shot — should be given at least 2 weeks before therapy begins.

The 2-week and 4-week intervals are not arbitrary. Inactivated vaccines need roughly that long to mount a measurable antibody response; live vaccines need longer because the attenuated virus replicates and can theoretically cause disseminated disease once immunosuppression begins. When I see a 2-week window offered for MMR in a child starting methotrexate next month, I push back. The 4-week interval exists because a child who seroconverts on day 12 but starts a biologic on day 13 is, in practical terms, unvaccinated.

For the trial team, I keep the timing matrix short:

Two clinical points are routinely missed. First, LAIV — the live attenuated influenza vaccine delivered as a nasal spray — is contraindicated once immunosuppression starts, and is sometimes the only influenza product stocked at autumn school-based clinics. Parents and primary care teams need explicit written instructions that the inactivated flu shot is the only acceptable product during the immunosuppression window. Second, rotavirus vaccine is age-capped (first dose by 14 weeks 6 days, last dose by 8 months 0 days) and is live; if an infant is approaching the immunosuppression threshold within those age windows, the series must be completed before therapy or it is forfeit.

Defining high-dose corticosteroid thresholds and risk

Corticosteroids are the most common immunosuppressant in pediatric practice and the one most likely to be started emergently. The threshold that flips a child from "low-level immunosuppression, live vaccines may still be considered with caution" to "high-level, live vaccines contraindicated" is well defined in pediatric guidelines: prednisone at ≥2 mg/kg/day, or a total daily dose of ≥20 mg in any child weighing more than 10 kg, sustained for ≥14 consecutive days. Below that threshold, the immune system is generally competent enough for the benefits of MMR or varicella catch-up to outweigh theoretical risk; above it, vaccine-strain disseminated disease is the concrete concern.

In practice, I see two failure modes. The first is the slow-burn failure: a child with a chronic autoimmune condition placed on 1.5 mg/kg/day prednisone for several weeks, with the dose creeping up during a flare, crossing the high-dose threshold without a documented immunization review. The second is the pulse-dose failure: a child admitted for severe asthma or a rheumatologic flare who receives three to five days of high-dose IV methylprednisolone, then transitions to oral prednisone at the threshold dose — at which point the live-vaccine contraindication has effectively been triggered.

The action item on a pediatric pre immunosuppression vaccine checklist is the same in both scenarios: capture the cumulative corticosteroid exposure, not just the current day's prescription. If the child is at or above the high-dose threshold for ≥14 days within the prior month, treat them as immunosuppressed for the purposes of live-vaccine decision-making.

High-dose corticosteroid exposure is not a single-day event. It is the cumulative 14-day pattern that determines whether live vaccines remain an option.

Managing household contacts to build protective immunity

Children do not live in isolation. A pediatric pre immunosuppression vaccine checklist that stops at the patient is incomplete, because the most common exposures — siblings, parents, grandparents, daycare contacts — will continue to circulate respiratory and vaccine-preventable pathogens throughout the immunosuppression period. The guideline-driven answer is a "cocoon" or protective ring strategy: every household contact and close family member should be fully vaccinated with all routine inactivated vaccines and the annual influenza vaccine.

The reasoning is straightforward and the data behind it is robust. Inactivated vaccines cannot be transmitted. The annual inactivated influenza shot given to parents and siblings reduces the probability of an influenza introduction into the home — a meaningful intervention because influenza in an immunosuppressed child frequently escalates to hospitalization, with bacterial superinfection by pneumococcus or staphylococcus the typical pathway to severe disease.

The harder question is live vaccines in household contacts. MMR, MMRV, and varicella vaccines are shedding-attenuated, and the theoretical risk of transmission to an immunosuppressed contact has historically been the reason some families decline. Current guidance is clear: healthy household contacts should receive routine live vaccines per the standard schedule, with a preference for inactivated influenza (IIV) over LAIV. Transmission of vaccine-strain varicella from a recently vaccinated sibling is biologically possible but extremely rare in real-world data; the alternative — an unvaccinated sibling who contracts wild-type varicella and brings it home — is a far greater risk.

Cocooning is a low-yield conversation in absolute terms and a high-yield conversation in the cases where it matters. In my trial cohorts, the parents who decline household influenza vaccination and then have a sibling bring home influenza B in February are the parents I meet in the hospital, not the clinic.

Post-therapy reconstitution and resuming immunization

The decision to stop or taper immunosuppressive therapy does not flip the patient back to baseline immune competence on day one. Pediatric guidelines are explicit on the deferral interval: live vaccines are typically withheld for at least 3 months after discontinuation of immunosuppressive therapy, and for up to 6 months depending on the specific drug and degree of immune reconstitution. B-cell depleting agents (rituximab) in particular require the longer interval, because B-cell repopulation lags behind clinical remission and antibody responses to live vaccines can be blunted or absent during the recovery window.

For inactivated vaccines during and after therapy, the principle is different: these can be administered, but the immunogenicity may be reduced. I counsel families to expect that post-therapy booster doses may be necessary, and that antibody titer checks for hepatitis B, measles, and varicella are reasonable at the 6-month mark to confirm protective status before assuming prior immunity. This is also the window in which catch-up HPV, meningococcal B, and the second-dose varicella (if age-eligible and not previously administered) become actionable again.

The pediatric pre immunosuppression vaccine checklist therefore has a tail: it does not end when therapy begins, it ends when the child has documented protective titers across the relevant antigens after immune reconstitution.

Balancing urgent clinical needs with vaccination protocols

The most common pushback I hear from referring teams is timing. A child with severe autoimmune hepatitis, a rheumatologic flare threatening joints, or a malignancy requiring chemotherapy initiation does not have a 4-week runway. In those cases, the correct answer is rarely "delay therapy to complete vaccines." It is "deliver inactivated vaccines now, defer live vaccines, document the deferral, and build the post-therapy catch-up plan into the treatment calendar from day one."

The 2025 IDSA guideline and the 2013 IDSA Clinical Practice Guideline that preceded it both make room for this triage. The hierarchy, in my reading:

1. Administer all due inactivated vaccines immediately, regardless of how soon therapy starts. Even a partial antibody response is better than none.

2. Defer live vaccines explicitly and document the deferral with a target resumption date in the chart.

3. Initiate immunosuppressive therapy when clinically indicated; do not delay urgent treatment for non-urgent vaccination.

4. Build the post-therapy catch-up plan before discharge, so the primary care team and the specialty team are aligned.

This is where the checklist format earns its keep. The items are not aspirational; they are operational. A child entering immunosuppression should leave the pre-treatment visit with a documented immunization record, a list of vaccines deferred, a list of household contacts reviewed for vaccination status, and a follow-up plan that names the clinician responsible for post-reconstitution catch-up. Without that paperwork trail, the deferred vaccines stay deferred indefinitely, and the child accrues an immunity debt that compounds every year they remain on therapy.

The four-week and two-week intervals are not bureaucracy. They are the immunological distance between a vaccinated child and an unprotected one during the highest-risk phase of their disease course.

The sober verdict: pediatric pre immunosuppression vaccine checklists work when they are built into the treatment initiation workflow, not added to it. The rheumatology or oncology clinic that runs an immunization review at the same visit that biologic therapy is ordered is the clinic that catches the missed varicella booster. The clinic that treats vaccination as a primary care responsibility — handed off without a handoff document — is the clinic whose patients arrive at my trial desk with seronegative measles and a six-month live-vaccine deferral already in the chart. The difference is process, not parental compliance, and it is the difference I spend the most time correcting at trial enrollment.